-+ 0.00%
-+ 0.00%
-+ 0.00%

U.S. FDA APPROVES AKEEGA® AS THE FIRST PRECISION THERAPY FOR BRCA2-MUTATED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH 54% REDUCTION IN DISEASE PROGRESSION VS STANDARD OF CARE*

Reuters·12/13/2025 01:25:51

Please log in to view news